Charles J. Ryan, MD, University of California, discusses the advantages of giving androgen receptor targeting earlier to advanced disease patients, and a review of the STAMPEDE results.
To view slides from Dr. Ryan’s androgen receptor presentation at the 18th Annual Future Directions in Urology Symposium, click here.
To view slides from Dr. Ryan’s STAMPEDE results presentation at the 18th Annual Future Directions in Urology Symposium, click here.
“Keywords: prostate cancer, androgen receptor, STAMPEDE
ABOUT THE AUTHOR
Charles J. Ryan, MD, is the B.J. Kennedy Chair in Clinical Medical Oncology and Director of the Division of Hematology, Oncology and Transplantation at the University of Minnesota. He previously held the positions of Professor of Clinical Medicine and Urology and Clinical Program Leader for Genitourinary Medical Oncology at the University of California, San Francisco Helen Diller Family Comprehensive Cancer Center.
Dr. Ryan graduated magna cum laude with a BA in Philosophy from Marquette University. He then went on to attend the University of Wisconsin Medical School. He trained at the University of Wisconsin Hospital and Clinics, serving as Chief Resident, and at Memorial Sloan-Kettering Cancer Center in New York. He has served as Co-Chair of the National Cancer Institute’s Prostate Cancer Task Force and as the Leader of Advanced Prostate Cancer Care for the Alliance for Clinical Trials in Oncology, a national clinical trials group. His research focuses on the development of new treatments for advanced prostate cancer, as well as supportive care for prostate cancer patients. He has published over 100 articles and chapters in the world’s leading medical journals.
